Published in Nature on August 14, 2003
Molecular mechanisms of necroptosis: an ordered cellular explosion. Nat Rev Mol Cell Biol (2010) 9.06
Breaking the chains: structure and function of the deubiquitinases. Nat Rev Mol Cell Biol (2009) 8.85
Ubiquitin signalling in the NF-kappaB pathway. Nat Cell Biol (2005) 8.06
Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell (2007) 7.10
Involvement of linear polyubiquitylation of NEMO in NF-kappaB activation. Nat Cell Biol (2009) 6.62
STAT3 activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer. Mol Cell (2010) 5.67
Ubiquitylation and cell signaling. EMBO J (2005) 4.65
Oncogenic activation of NF-kappaB. Cold Spring Harb Perspect Biol (2010) 3.30
siRNA-mediated off-target gene silencing triggered by a 7 nt complementation. Nucleic Acids Res (2005) 3.21
A ubiquitin replacement strategy in human cells reveals distinct mechanisms of IKK activation by TNFalpha and IL-1beta. Mol Cell (2009) 2.81
The tumour suppressor CYLD is a negative regulator of RIG-I-mediated antiviral response. EMBO Rep (2008) 2.65
NF-κB addiction and its role in cancer: 'one size does not fit all'. Oncogene (2010) 2.56
Proteomic investigations reveal a role for RNA processing factor THRAP3 in the DNA damage response. Mol Cell (2012) 2.51
Ubiquitination in signaling to and activation of IKK. Immunol Rev (2012) 2.28
Zinc-finger protein A20, a regulator of inflammation and cell survival, has de-ubiquitinating activity. Biochem J (2004) 2.23
Protein partners of deubiquitinating enzymes. Biochem J (2008) 2.15
Linear polyubiquitination: a new regulator of NF-kappaB activation. EMBO Rep (2009) 2.15
Exploitation of eukaryotic ubiquitin signaling pathways by effectors translocated by bacterial type III and type IV secretion systems. PLoS Pathog (2007) 2.14
Deubiquitinating enzyme CYLD negatively regulates the ubiquitin-dependent kinase Tak1 and prevents abnormal T cell responses. J Exp Med (2007) 2.14
The Notch/Hes1 pathway sustains NF-κB activation through CYLD repression in T cell leukemia. Cancer Cell (2010) 2.09
The deubiquitinating enzyme USP2a regulates the p53 pathway by targeting Mdm2. EMBO J (2007) 2.07
Impaired regulation of NF-kappaB and increased susceptibility to colitis-associated tumorigenesis in CYLD-deficient mice. J Clin Invest (2006) 2.02
Harnessing synthetic lethal interactions in anticancer drug discovery. Nat Rev Drug Discov (2011) 2.01
Deubiquitinases in the regulation of NF-κB signaling. Cell Res (2010) 2.00
Phosphorylation of the tumor suppressor CYLD by the breast cancer oncogene IKKepsilon promotes cell transformation. Mol Cell (2009) 2.00
Classical and/or alternative NF-kappaB pathway activation in multiple myeloma. Blood (2010) 1.96
Regulation of RIP1 kinase signalling at the crossroads of inflammation and cell death. Nat Rev Mol Cell Biol (2013) 1.89
Expanding role of ubiquitination in NF-κB signaling. Cell Res (2010) 1.89
Yersinia virulence factor YopJ acts as a deubiquitinase to inhibit NF-kappa B activation. J Exp Med (2005) 1.85
A pervasive role of ubiquitin conjugation in activation and termination of IkappaB kinase pathways. EMBO Rep (2005) 1.79
Regulation of NF-κB by deubiquitinases. Immunol Rev (2012) 1.78
Regulation of IkappaB kinase-related kinases and antiviral responses by tumor suppressor CYLD. J Biol Chem (2008) 1.78
The translation initiation factor 3f (eIF3f) exhibits a deubiquitinase activity regulating Notch activation. PLoS Biol (2010) 1.77
The Rsp5 ubiquitin ligase is coupled to and antagonized by the Ubp2 deubiquitinating enzyme. EMBO J (2005) 1.76
Essential role of ubiquitin-specific protease 8 for receptor tyrosine kinase stability and endocytic trafficking in vivo. Mol Cell Biol (2007) 1.76
DNA damage-dependent NF-κB activation: NEMO turns nuclear signaling inside out. Immunol Rev (2012) 1.74
Gene disruption study reveals a nonredundant role for TRIM21/Ro52 in NF-kappaB-dependent cytokine expression in fibroblasts. J Immunol (2009) 1.73
The ubiquitin system, disease, and drug discovery. BMC Biochem (2008) 1.73
TANK is a negative regulator of Toll-like receptor signaling and is critical for the prevention of autoimmune nephritis. Nat Immunol (2009) 1.72
Suppression of cancer cell growth by promoting cyclin D1 degradation. Mol Cell (2009) 1.72
Modulation of NF-κB signalling by microbial pathogens. Nat Rev Microbiol (2011) 1.64
A TRAIL receptor-dependent synthetic lethal relationship between MYC activation and GSK3beta/FBW7 loss of function. Proc Natl Acad Sci U S A (2005) 1.64
Regulation of MITF stability by the USP13 deubiquitinase. Nat Commun (2011) 1.62
The tumor suppressor CYLD regulates entry into mitosis. Proc Natl Acad Sci U S A (2007) 1.61
Regulation of the deubiquitinating enzyme CYLD by IkappaB kinase gamma-dependent phosphorylation. Mol Cell Biol (2005) 1.61
Pathogenetic importance and therapeutic implications of NF-κB in lymphoid malignancies. Immunol Rev (2012) 1.60
Down-regulation of CYLD expression by Snail promotes tumor progression in malignant melanoma. J Exp Med (2009) 1.59
Activity-based ubiquitin-specific protease (USP) profiling of virus-infected and malignant human cells. Proc Natl Acad Sci U S A (2004) 1.59
Stabilization of the E3 ubiquitin ligase Nrdp1 by the deubiquitinating enzyme USP8. Mol Cell Biol (2004) 1.54
Defining the optimal parameters for hairpin-based knockdown constructs. RNA (2007) 1.48
Regulation of mitochondrial morphology by USP30, a deubiquitinating enzyme present in the mitochondrial outer membrane. Mol Biol Cell (2008) 1.48
Emerging roles for the non-canonical IKKs in cancer. Oncogene (2010) 1.48
Natural selection and infectious disease in human populations. Nat Rev Genet (2014) 1.48
pVHL acts as an adaptor to promote the inhibitory phosphorylation of the NF-kappaB agonist Card9 by CK2. Mol Cell (2007) 1.47
Hsp70 promotes TNF-mediated apoptosis by binding IKK gamma and impairing NF-kappa B survival signaling. Genes Dev (2004) 1.46
Signal processing by its coil zipper domain activates IKK gamma. Proc Natl Acad Sci U S A (2008) 1.46
The innate immune sensor NLRC3 attenuates Toll-like receptor signaling via modification of the signaling adaptor TRAF6 and transcription factor NF-κB. Nat Immunol (2012) 1.45
Transcriptional activation of polycomb-repressed genes by ZRF1. Nature (2010) 1.44
The tumor suppressor CYLD interacts with TRIP and regulates negatively nuclear factor kappaB activation by tumor necrosis factor. J Exp Med (2003) 1.44
Deubiquitinating enzymes as novel anticancer targets. Future Oncol (2007) 1.43
Suppression of the deubiquitinating enzyme USP5 causes the accumulation of unanchored polyubiquitin and the activation of p53. J Biol Chem (2008) 1.43
The IkappaB kinase complex: master regulator of NF-kappaB signaling. Immunol Res (2008) 1.43
Ubiquitin-specific peptidase 21 inhibits tumor necrosis factor alpha-induced nuclear factor kappaB activation via binding to and deubiquitinating receptor-interacting protein 1. J Biol Chem (2009) 1.43
Regulation of catalytic activities of HECT ubiquitin ligases. Biochem Biophys Res Commun (2007) 1.42
Distinct regulation of Ubc13 functions by the two ubiquitin-conjugating enzyme variants Mms2 and Uev1A. J Cell Biol (2005) 1.41
IKK biology. Immunol Rev (2012) 1.40
TRAF family proteins link PKR with NF-kappa B activation. Mol Cell Biol (2004) 1.40
Specific recognition of linear polyubiquitin by A20 zinc finger 7 is involved in NF-κB regulation. EMBO J (2012) 1.39
Using functional genetics to understand breast cancer biology. Cold Spring Harb Perspect Biol (2010) 1.39
Polyubiquitin binding and disassembly by deubiquitinating enzymes. Chem Rev (2009) 1.36
A cytosolic ATM/NEMO/RIP1 complex recruits TAK1 to mediate the NF-kappaB and p38 mitogen-activated protein kinase (MAPK)/MAPK-activated protein 2 responses to DNA damage. Mol Cell Biol (2011) 1.36
Reverse the curse--the role of deubiquitination in cell cycle control. Curr Opin Cell Biol (2008) 1.31
Tumor mapping in 2 large multigenerational families with CYLD mutations: implications for disease management and tumor induction. Arch Dermatol (2009) 1.28
Inactivation of the CYLD deubiquitinase by HPV E6 mediates hypoxia-induced NF-kappaB activation. Cancer Cell (2008) 1.27
The sequestosome 1/p62 attenuates cytokine gene expression in activated macrophages by inhibiting IFN regulatory factor 8 and TNF receptor-associated factor 6/NF-kappaB activity. J Immunol (2009) 1.26
Targeting the ubiquitin-proteasome system for cancer therapy. Cancer Sci (2008) 1.24
LUBAC-Recruited CYLD and A20 Regulate Gene Activation and Cell Death by Exerting Opposing Effects on Linear Ubiquitin in Signaling Complexes. Cell Rep (2015) 1.23
The multiple layers of ubiquitin-dependent cell cycle control. Chem Rev (2009) 1.22
Tumor suppressor CYLD acts as a negative regulator for non-typeable Haemophilus influenza-induced inflammation in the middle ear and lung of mice. PLoS One (2007) 1.22
CYLD negatively regulates cell-cycle progression by inactivating HDAC6 and increasing the levels of acetylated tubulin. EMBO J (2009) 1.21
Emerging role of Lys-63 ubiquitination in protein kinase and phosphatase activation and cancer development. Oncogene (2010) 1.21
Ubiquitin-specific peptidase 20 targets TRAF6 and human T cell leukemia virus type 1 tax to negatively regulate NF-kappaB signaling. J Virol (2011) 1.21
Minimizing off-target effects by using diced siRNAs for RNA interference. J RNAi Gene Silencing (2006) 1.20
Ubiquitin in NF-kappaB signaling. Chem Rev (2009) 1.20
The BRG1- and hBRM-associated factor BAF57 induces apoptosis by stimulating expression of the cylindromatosis tumor suppressor gene. Mol Cell Biol (2005) 1.20
WDR20 regulates activity of the USP12 x UAF1 deubiquitinating enzyme complex. J Biol Chem (2010) 1.20
CYLD negatively regulates transforming growth factor-β-signalling via deubiquitinating Akt. Nat Commun (2012) 1.18
RNA interference in biology and disease. Blood (2005) 1.18
Deubiquitylating enzymes and disease. BMC Biochem (2008) 1.17
Regulation of NF-κB by ubiquitination. Curr Opin Immunol (2013) 1.17
miR-486 sustains NF-κB activity by disrupting multiple NF-κB-negative feedback loops. Cell Res (2012) 1.17
USP17 regulates Ras activation and cell proliferation by blocking RCE1 activity. J Biol Chem (2009) 1.14
The E3 ligase Itch and deubiquitinase Cyld act together to regulate Tak1 and inflammation. Nat Immunol (2011) 1.14
Emerging therapies targeting the ubiquitin proteasome system in cancer. J Clin Invest (2014) 1.13
Specificity of the BRISC deubiquitinating enzyme is not due to selective binding to Lys63-linked polyubiquitin. J Biol Chem (2009) 1.13
Dimerization of the I kappa B kinase-binding domain of NEMO is required for tumor necrosis factor alpha-induced NF-kappa B activity. Mol Cell Biol (2006) 1.10
NF-κB induction of the SUMO protease SENP2: A negative feedback loop to attenuate cell survival response to genotoxic stress. Mol Cell (2011) 1.09
Update of cylindromatosis gene (CYLD) mutations in Brooke-Spiegler syndrome: novel insights into the role of deubiquitination in cell signaling. Hum Mutat (2009) 1.09
Systematic analysis of the physiological importance of deubiquitinating enzymes. PLoS One (2012) 1.08
Genetics of skin appendage neoplasms and related syndromes. J Med Genet (2005) 1.08
Gene expression profiling predicts clinical outcome of breast cancer. Nature (2002) 71.36
A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med (2002) 58.15
A system for stable expression of short interfering RNAs in mammalian cells. Science (2002) 35.21
A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell (2007) 11.21
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature (2012) 9.39
A genomic and functional inventory of deubiquitinating enzymes. Cell (2005) 9.36
A large-scale RNAi screen in human cells identifies new components of the p53 pathway. Nature (2004) 8.67
An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res (2008) 8.12
Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell (2002) 7.88
Minimizing the risk of reporting false positives in large-scale RNAi screens. Nat Methods (2006) 5.96
Regulation of monoubiquitinated PCNA by DUB autocleavage. Nat Cell Biol (2006) 4.67
Converting a breast cancer microarray signature into a high-throughput diagnostic test. BMC Genomics (2006) 4.57
Plasminogen activator inhibitor-1 is a critical downstream target of p53 in the induction of replicative senescence. Nat Cell Biol (2006) 4.54
The deubiquitinating enzyme USP1 regulates the Fanconi anemia pathway. Mol Cell (2005) 4.40
The KLF4 tumour suppressor is a transcriptional repressor of p53 that acts as a context-dependent oncogene. Nat Cell Biol (2005) 4.29
Enabling personalized cancer medicine through analysis of gene-expression patterns. Nature (2008) 4.24
MED12 controls the response to multiple cancer drugs through regulation of TGF-β receptor signaling. Cell (2012) 4.01
Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res (2009) 3.77
Protein phosphatase 2A regulatory subunits and cancer. Biochim Biophys Acta (2008) 3.74
Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. Cancer Res (2008) 3.70
Human immunodeficiency virus type 1 escapes from RNA interference-mediated inhibition. J Virol (2004) 3.23
ZNF423 is critically required for retinoic acid-induced differentiation and is a marker of neuroblastoma outcome. Cancer Cell (2009) 2.93
An shRNA barcode screen provides insight into cancer cell vulnerability to MDM2 inhibitors. Nat Chem Biol (2006) 2.91
The human tumor antigen PRAME is a dominant repressor of retinoic acid receptor signaling. Cell (2005) 2.73
Reversal of senescence in mouse fibroblasts through lentiviral suppression of p53. J Biol Chem (2003) 2.14
NF1 is a tumor suppressor in neuroblastoma that determines retinoic acid response and disease outcome. Cell (2010) 1.81
Expression profiling predicts outcome in breast cancer. Breast Cancer Res (2002) 1.81
The translation initiation factor 3f (eIF3f) exhibits a deubiquitinase activity regulating Notch activation. PLoS Biol (2010) 1.77
A senescence rescue screen identifies BCL6 as an inhibitor of anti-proliferative p19(ARF)-p53 signaling. Genes Dev (2002) 1.65
A chemical-genetic screen reveals a mechanism of resistance to PI3K inhibitors in cancer. Nat Chem Biol (2011) 1.65
p19(ARF) /p14(ARF) controls oncogenic functions of signal transducer and activator of transcription 3 in hepatocellular carcinoma. Hepatology (2011) 1.60
E2F transcriptional repressor complexes are critical downstream targets of p19(ARF)/p53-induced proliferative arrest. Cancer Cell (2002) 1.59
Gene expression profiling in follicular lymphoma to assess clinical aggressiveness and to guide the choice of treatment. Blood (2004) 1.56
Mechanism of USP7/HAUSP activation by its C-terminal ubiquitin-like domain and allosteric regulation by GMP-synthetase. Mol Cell (2011) 1.56
Re-evaluating cell-cycle regulation by E2Fs. Cell (2006) 1.46
TBX-3, the gene mutated in Ulnar-Mammary Syndrome, is a negative regulator of p19ARF and inhibits senescence. J Biol Chem (2001) 1.46
E2F-7: a distinctive E2F family member with an unusual organization of DNA-binding domains. Oncogene (2004) 1.44
Identification of recurrent FGFR3 fusion genes in lung cancer through kinome-centred RNA sequencing. J Pathol (2013) 1.38
Involvement of MINK, a Ste20 family kinase, in Ras oncogene-induced growth arrest in human ovarian surface epithelial cells. Mol Cell (2005) 1.34
Genome-wide loss-of-function screen reveals an important role for the proteasome in HDAC inhibitor-induced apoptosis. Cancer Cell (2009) 1.33
A large scale shRNA barcode screen identifies the circadian clock component ARNTL as putative regulator of the p53 tumor suppressor pathway. PLoS One (2009) 1.29
Reduced NF1 expression confers resistance to EGFR inhibition in lung cancer. Cancer Discov (2014) 1.27
A functional screen identifies hDRIL1 as an oncogene that rescues RAS-induced senescence. Nat Cell Biol (2002) 1.25
New tools for functional mammalian cancer genetics. Nat Rev Cancer (2003) 1.22
PR72, a novel regulator of Wnt signaling required for Naked cuticle function. Genes Dev (2005) 1.21
A reversible gene trap collection empowers haploid genetics in human cells. Nat Methods (2013) 1.17
Senescence, wound healing and cancer: the PAI-1 connection. Cell Cycle (2006) 1.17
TSPYL5 suppresses p53 levels and function by physical interaction with USP7. Nat Cell Biol (2010) 1.13
A causal role for the human tumor antigen preferentially expressed antigen of melanoma in cancer. Cancer Res (2006) 1.09
Transforming growth factor-beta requires its target plasminogen activator inhibitor-1 for cytostatic activity. J Biol Chem (2008) 1.09
A functional genetic screen identifies retinoic acid signaling as a target of histone deacetylase inhibitors. Proc Natl Acad Sci U S A (2007) 1.07
PR130 is a modulator of the Wnt-signaling cascade that counters repression of the antagonist Naked cuticle. Proc Natl Acad Sci U S A (2006) 1.07
Taming the dragon: genomic biomarkers to individualize the treatment of cancer. Nat Med (2011) 1.05
The deubiquitinating enzyme USP26 is a regulator of androgen receptor signaling. Mol Cancer Res (2010) 1.04
Synthetic lethal vulnerabilities of cancer. Annu Rev Pharmacol Toxicol (2014) 1.03
Cardiac glycosides induce cell death in human cells by inhibiting general protein synthesis. PLoS One (2009) 1.00
Cancer: cues for migration. Nature (2003) 0.97
A RNA interference screen identifies the protein phosphatase 2A subunit PR55gamma as a stress-sensitive inhibitor of c-SRC. PLoS Genet (2007) 0.95
UNC45A confers resistance to histone deacetylase inhibitors and retinoic acid. Mol Cancer Res (2009) 0.95
Inhibition of the PI3K pathway: hope we can believe in? Clin Cancer Res (2010) 0.94
An α-E-catenin (CTNNA1) mutation in hereditary diffuse gastric cancer. J Pathol (2013) 0.93
Understanding resistance to targeted cancer drugs through loss of function genetic screens. Drug Resist Updat (2012) 0.93
High incidence of thymic epithelial tumors in E2F2 transgenic mice. J Biol Chem (2003) 0.91
Constitutive E2F1 overexpression delays endochondral bone formation by inhibiting chondrocyte differentiation. Mol Cell Biol (2003) 0.91
TGF-β: an emerging player in drug resistance. Cell Cycle (2013) 0.90
A gene signature for late distant metastasis in breast cancer identifies a potential mechanism of late recurrences. Mol Oncol (2013) 0.90
A functional genetic screen identifies TFE3 as a gene that confers resistance to the anti-proliferative effects of the retinoblastoma protein and transforming growth factor-beta. J Biol Chem (2006) 0.89
Suppression of the p53-dependent replicative senescence response by lysophosphatidic acid signaling. Mol Cancer Res (2008) 0.87
Identification of oncostatin M as a STAT5-dependent mediator of bone marrow remodeling in KIT D816V-positive systemic mastocytosis. Am J Pathol (2011) 0.87
Interleukin-1R-associated kinase 2 is a novel modulator of the transforming growth factor beta signaling cascade. Mol Cancer Res (2010) 0.87
Deoxycytidine kinase is overexpressed in poor outcome breast cancer and determines responsiveness to nucleoside analogs. Breast Cancer Res Treat (2011) 0.86
Molecular basis of the anti-cancer effects of histone deacetylase inhibitors. Int J Biochem Cell Biol (2008) 0.86
Functional identification of LRF as an oncogene that bypasses RASV12-induced senescence via upregulation of CYCLIN E. Carcinogenesis (2009) 0.85
Sorafenib synergizes with metformin in NSCLC through AMPK pathway activation. Int J Cancer (2014) 0.84
Resistance to targeted cancer drugs through hepatocyte growth factor signaling. Cell Cycle (2014) 0.84
Ubiquitin-specific protease 4 inhibits mono-ubiquitination of the master growth factor signaling kinase PDK1. PLoS One (2012) 0.83
Genetic and functional studies implicate synaptic overgrowth and ring gland cAMP/PKA signaling defects in the Drosophila melanogaster neurofibromatosis-1 growth deficiency. PLoS Genet (2013) 0.83
Functional annotation of deubiquitinating enzymes using RNA interference. Methods Enzymol (2005) 0.80
Candidate biomarkers of response to an experimental cancer drug identified through a large-scale RNA interference genetic screen. Clin Cancer Res (2009) 0.80
Wip-ing out cancer. Nat Genet (2004) 0.79
Cancer: Entangled pathways. Nature (2008) 0.79
An in vivo functional genetic screen reveals a role for the TRK-T3 oncogene in tumor progression. Oncogene (2004) 0.77
TOPS: a versatile software tool for statistical analysis and visualization of combinatorial gene-gene and gene-drug interaction screens. BMC Bioinformatics (2014) 0.76
Functional drug-gene interactions in lung cancer. Expert Rev Mol Diagn (2012) 0.76
Functional subtyping of breast cancer. Cancer Discov (2011) 0.75
Are short-term or long-term recurrence rates more important in breast cancer screening? Ann Intern Med (2008) 0.75
Giving Rho(d) directions. Nat Chem Biol (2010) 0.75